{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:21:00Z","timestamp":1784535660318,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010511","name":"Clinical and Translational Science Institute, University of California, San Francisco","doi-asserted-by":"publisher","award":["UL1TR000124UCLA"],"award-info":[{"award-number":["UL1TR000124UCLA"]}],"id":[{"id":"10.13039\/100010511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ymgmr.2020.100700","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T15:52:17Z","timestamp":1609429937000},"page":"100700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Marina","family":"Dutra-Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"R\u00fcnger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zyza","family":"Alandy-Dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Freedkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Ercelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jousef","family":"Alandy-Dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Pahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kimonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ymgmr.2020.100700_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med."},{"issue":"4198","key":"10.1016\/j.ymgmr.2020.100700_bb0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.1138375","article-title":"Exploring cells with a centrifuge","volume":"189","author":"Duve","year":"1975","journal-title":"Science."},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100700_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0020","series-title":"The Metabolic and Molecular Bases of Inherited Diseases","first-page":"3733","article-title":"Alpha-galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100700_bb0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","article-title":"Newborn screening for lysosomal storage disorders","volume":"39","author":"Matern","year":"2015","journal-title":"Semin. Perinatol."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100700_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"9","key":"10.1016\/j.ymgmr.2020.100700_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med."},{"issue":"4","key":"10.1016\/j.ymgmr.2020.100700_bb0040","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100700_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/j.ymgmr.2020.100700_bb0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"Warnock","year":"2015","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100700_bb0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10897-015-9879-8","article-title":"Newborn screening for lysosomal storage disorders: views of genetic healthcare providers","volume":"25","author":"Lisi","year":"2016","journal-title":"J. Genet. Couns."},{"issue":"7","key":"10.1016\/j.ymgmr.2020.100700_bb0060","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamapediatrics.2018.0263","article-title":"Incidence of 4 lysosomal storage disorders from 4 years of newborn screening","volume":"172","author":"Hopkins","year":"2018","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0065","unstructured":"Replagal\u00ae Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000369\/WC500053612.pdf (2014), Accessed 19th Oct 2017."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0070","unstructured":"Fabrazyme\u00ae Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103979s5135lbl.pdf (2010), Accessed 19th Oct 2017."},{"issue":"7","key":"10.1016\/j.ymgmr.2020.100700_bb0075","first-page":"CD006663","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100700_bb0080","first-page":"173","volume":"77","author":"Ripeau","year":"2017","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.ymgmr.2020.100700_bb0085","unstructured":"Amicus Therapeutics. Galafold\u2122 (Migalastat) Capsules, for Oral Use: US Prescribing Information. 2018. https:\/\/www.fda.gov\/. Accessed 18 Oct 2018."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0090","first-page":"3","article-title":"Lipid profile in adult patients with Fabry disease - Ten-year follow up","volume":"13","author":"Stepien","year":"2017","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100700_bb0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/bjophthalmol-2016-310088","article-title":"Conjunctival lymphangiectasia associated with classic Fabry disease","volume":"102","author":"Sivley","year":"2018","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100700_bb0100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1442-9071.2005.00990.x","article-title":"Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre","volume":"33","author":"Nguyen","year":"2005","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0105","first-page":"45","article-title":"Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with Agalsidase Beta: data from the Fabry registry","volume":"38","author":"Wilcox","year":"2018","journal-title":"JIMD Rep."},{"issue":"Pt 1","key":"10.1016\/j.ymgmr.2020.100700_bb0110","first-page":"143","article-title":"Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease","volume":"130","author":"Ries","year":"2007","journal-title":"Brain."},{"issue":"12","key":"10.1016\/j.ymgmr.2020.100700_bb0115","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/GIM.0b013e31815cb197","article-title":"Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density","volume":"9","author":"Mersebach","year":"2007","journal-title":"Genet Med."},{"issue":"8","key":"10.1016\/j.ymgmr.2020.100700_bb0120","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","article-title":"Prevalence of uncontrolled hypertension in patients with Fabry disease","volume":"19","author":"Kleinert","year":"2006","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100700_bb0125","first-page":"489","article-title":"Novel GLA gene mutations in two Chinese families with classic Fabry disease","volume":"22","author":"Wang","year":"2005","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi (Chinese journal of medical genetics)."},{"issue":"9","key":"10.1016\/j.ymgmr.2020.100700_bb0130","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent Agalsidase effects on kidney histology in Fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0135","first-page":"31","article-title":"Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events","volume":"14","author":"Beck","year":"2017","journal-title":"Mol Genet Metab Rep."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0140","first-page":"100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol Genet Metab Rep."},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100700_bb0145","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100700_bb0150","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100700_bb0155","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgmr.2020.100700_bb0160","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0165","first-page":"41","article-title":"Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina","volume":"12","author":"Jaurretche","year":"2017","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100700_bb0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","article-title":"Arrhythmia and clinical cardiac findings in children with Anderson-Fabry disease","volume":"120","author":"Wilson","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ymgmr.2020.100700_bb0175","doi-asserted-by":"crossref","first-page":"e0175929","DOI":"10.1371\/journal.pone.0175929","article-title":"Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease","volume":"12","author":"Chang","year":"2017","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.ymgmr.2020.100700_bb0180","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage Progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100700_bb0185","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10545-010-9166-7","article-title":"Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4+919G\u2192A)","volume":"33","author":"Lin","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100700_bb0190","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100700_bb0195","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0200","first-page":"37","article-title":"Sleep disturbance, obstructive sleep Apnoea and abnormal periodic leg movements: very common problems in Fabry disease","volume":"31","author":"Talbot","year":"2017","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0205","first-page":"13","article-title":"Treatment of depression in adults with Fabry disease","volume":"38","author":"Ali","year":"2018","journal-title":"JIMD Rep."},{"issue":"7","key":"10.1016\/j.ymgmr.2020.100700_bb0210","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry disease: practical recommendations for diagnosis and treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci Ther."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2377-13-47","article-title":"Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study","volume":"13","author":"\u00dc\u00e7eyler","year":"2013","journal-title":"BMC Neurol."},{"issue":"9","key":"10.1016\/j.ymgmr.2020.100700_bb0220","doi-asserted-by":"crossref","first-page":"e0137603","DOI":"10.1371\/journal.pone.0137603","article-title":"Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease","volume":"10","author":"Lelieveld","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100700_bb0225","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgmr.2020.100700_bb0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1012428009627","article-title":"Cardiac manifestations in Fabry disease","volume":"24","author":"Linhart","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"issue":"9","key":"10.1016\/j.ymgmr.2020.100700_bb0235","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.ymgmr.2020.100700_bb0240","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1210\/jc.2006-0858","article-title":"Endocrine dysfunction in patients with Fabry disease","volume":"91","author":"Faggiano","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"439","key":"10.1016\/j.ymgmr.2020.100700_bb0245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1651-2227.2002.tb03112.x","article-title":"Endothelial markers and homocysteine in patients with classic Fabry disease","volume":"91","author":"Demuth","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgmr.2020.100700_bb0250","first-page":"904141","article-title":"Evaluation of the EndoPAT as a tool to assess endothelial function","volume":"2012","author":"Moerland","year":"2012","journal-title":"Int J Vasc Med."},{"issue":"4","key":"10.1016\/j.ymgmr.2020.100700_bb0255","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000502907","article-title":"Early biomarkers of Fabry nephropathy: a review of the literature","volume":"143","author":"Riccio","year":"2019","journal-title":"Nephron."},{"issue":"6","key":"10.1016\/j.ymgmr.2020.100700_bb0260","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1039\/C4MB00707G","article-title":"Early markers of Fabry disease revealed by proteomics","volume":"11","author":"Matafora","year":"2015","journal-title":"Mol. BioSyst."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100700_bb0265","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100700_bb0270","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02186.x","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgmr.2020.100700_bb0275","first-page":"S172","article-title":"Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy","volume":"2","author":"Desnick","year":"2006","journal-title":"Nephrol Ther."},{"issue":"11","key":"10.1016\/j.ymgmr.2020.100700_bb0280","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00431-009-0937-9","article-title":"Fabry disease in children and the effects of enzyme replacement treatment","volume":"168","author":"Pintos-Morell","year":"2009","journal-title":"Eur. J. Pediatr."},{"issue":"9","key":"10.1016\/j.ymgmr.2020.100700_bb0285","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426920301464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426920301464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:51:47Z","timestamp":1762001507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426920301464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":57,"alternative-id":["S2214426920301464"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100700","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100700"}}